Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.

28 Mar 2017
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
Editor's Recommendations